Laryngeal Cancer Microbiome Study Reveals Parvimonas and Campylobacter as Potential Therapy Targets
The Laryngoscope · 2026-11-05
DOI: 10.1002/lary.71027 ↗Abstract
ABSTRACT Objective Laryngeal cancer accounts for 40% of head and neck malignancies and 1% of all cancer‐related deaths worldwide. We evaluated the laryngeal cancer microbiome to identify cancer‐specific genera as potential treatment targets. Methods A prospective study was conducted using 57 laryngeal mucosal samples from 24 treatment‐naive laryngeal cancer patients and 33 patients who were undergoing otolaryngological surgery unrelated to oral or laryngeal diseases (01/2023–09/2025). DNA was extracted and amplified in triplicate, targeting the V3/V4 region of the 16S rRNA gene, followed by paired‐end 2 × 300 bp sequencing on the Illumina NextSeq 2000. Amplicon sequence variants were identified via DADA2 and assigned to genera using a naive Bayes classifier. Two samples with zero classified read pairs were excluded. Results Most patients were male (87.5% cancer, 66.7% controls) and smokers (83.3% cancer, 54.5% controls). Cancer patients' core laryngeal microbiomes uniquely contained Parvimonas (3.67%; 95% CI: 0.70%–6.64%), and Campylobacter (1.12%; 95% CI: 0.60%–1.63%), while control patients' uniquely contained Corynebacterium (2.97%; 95% CI: 0.00%–7.67%) and Alloprevotella (1.34%; 95% CI: 0.64%–2.04%). Cancer samples were significantly enriched in 19 genera, notably Peptococcus (2.93, q = 0.0003), Campylobacter (1.68, q = 0.009), and Parvimonas (2.02, q = 0.03), compared to controls. Conclusions Laryngeal cancer patients' samples displayed microbial dysbiosis, with enrichment of microbes present in gastrointestinal cancers, cervical cancer, and inflammatory states; they also exhibited loss of immunoprotective taxa. These findings support that microbiome profiling can distinguish malignant mucosa and guide future studies targeting genera increased in cancer, including Parvimonas and Campylobacter . Level of Evidence 3.
EUVIMED